RT Journal Article
SR Electronic
T1 Genomic epidemiology of a densely sampled COVID-19 outbreak in China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.09.20033365
DO 10.1101/2020.03.09.20033365
A1 Geidelberg, Lily
A1 Boyd, Olivia
A1 Jorgensen, David
A1 Siveroni, Igor
A1 Nascimento, Fabricia F.
A1 Johnson, Robert
A1 Ragonnet-Cronin, Manon
A1 Fu, Han
A1 Wang, Haowei
A1 Xi, Xiaoyue
A1 Chen, Wei
A1 Liu, Dehui
A1 Chen, Yingying
A1 Tian, Mengmeng
A1 Tan, Wei
A1 Zai, Junjie
A1 Sun, Wanying
A1 Li, Jiandong
A1 Li, Junhua
A1 Volz, Erik M
A1 Li, Xingguang
A1 Nie, Qing
YR 2020
UL http://medrxiv.org/content/early/2020/09/16/2020.03.09.20033365.abstract
AB Analysis of genetic sequence data from the SARS-CoV-2 pandemic can provide insights into epidemic origins, worldwide dispersal, and epidemiological history. With few exceptions, genomic epidemiological analysis has focused on geographically distributed data sets with few isolates in any given location. Here we report an analysis of 20 whole SARS-CoV 2 genomes from a single relatively small and geographically constrained outbreak in Weifang, People’s Republic of China. Using Bayesian model-based phylodynamic methods, we estimate a mean basic reproduction number (R0) of 3.47 (95% highest posterior density interval: 1.78-5.47) in Weifang, and a mean effective reproduction number (Rt) that falls below 1 on February 2nd. We further estimate the number of infections through time and compare these estimates to confirmed diagnoses by the Weifang Centers for Disease Control. We find that these estimates are consistent with reported cases and there is unlikely to be a large undiagnosed burden of infection over the period we studied.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Centre funding from the UK Medical Research Council under a concordat with the UK Department for International Development. NIHR. J-IDEA. This work was also supported by a grant from the Special Project for Prevention and Control of Pneumonia of New Coronavirus Infection in Weifang Science and Technology Development Plan in 2020 (2020YQFK015) to Associate Senior Technologist Qing Nie. Role of the Funders: All funders of the study had no role in study design, data analysis, data interpretation, or writing of the report.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequences are deposited in GISAID. https://github.com/emvolz/weifang-sarscov2 https://www.gisaid.org/